Skip to main content

Advertisement

SpringerLink
Log in

Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study is to compare post-therapy third day and seventh day I-131 whole body scans (3DWBS and 7DWBS) in detecting lung or bone metastasis from well-differentiated thyroid cancer.

Materials and Methods

We enrolled 52 patients with lung or bone metastasis out of 1,152 patients who were treated with high-dose I-131 therapy from January 2008 to June 2009. All patients underwent 3DWBS and 7DWBS. I-131 avidity was classified into three grades: no uptake, suspicious for uptake, and definite uptake. We compared the presence and grades of metastatic lesions on each scan. We categorized all cases into three groups based on I-131 uptake on each scan and compared several clinical parameters including FDG uptake and thyroglobulin (Tg) level among the groups.

Results

Sixty metastatic cases from 52 patients (45 lung and 15 bone metastases) were included. In 35 cases, I-131-avid metastatic lesions were detected by both 3DWBS and 7DWBS (group A). In 15 cases, metastatic lesions were missed on 3DWBS but detected on 7DWBS (group B). In 10 cases, I-131 uptake was not detected on either 3DWBS or 7DWBS (group C). Ten of 45 cases (22.2%) of lung metastasis that were negative on 3DWBS were detected on 7DWBS (p = 0.002). Five of 15 cases (33.3%) of bone metastasis that were negative on 3DWBS were detected on 7DWBS (p = 0.0625). The serum Tg level (TSH stimulated) was significantly different among groups A, B, and C (p = 0.0030). However, after exclusion of cases without a history of I-131 therapy, there was no significant difference in serum Tg level among the groups (p = 0.2330). The number of cases with a prior history of metastasis was higher in group A than in group B (p = 0.0069). However, there was no significant difference in prior history of metastasis between groups A and C (p = 0.8107).

Conclusion

7DWBS showed more lung or bone metastatic lesions than 3DWBS. After high-dose I-131 therapy, 7DWBS should be considered regardless of the results of the 3DWBS for the diagnosis of lung or bone metastasis from well-differentiated thyroid cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1a-f
Fig. 2a-d
Fig. 3a-d
Fig. 4

Similar content being viewed by others

References

  1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.

    Article  PubMed  Google Scholar 

  2. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960–7.

    Article  CAS  PubMed  Google Scholar 

  3. Casara D, Rubello D, Saladini G, Gallo V, Masarotto G, Busnardo B. Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors in 214 patients. Tumori. 1991;77:432–6.

    CAS  PubMed  Google Scholar 

  4. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab. 1985;60:376–80.

    Article  CAS  PubMed  Google Scholar 

  5. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–63.

    Article  CAS  PubMed  Google Scholar 

  6. Mazzaferri EL. Treatment of carcinoma of follicular epithelium. In: Ingbar SH, Braverman LE, editors. The thyroid: a fundamental and clinical text, 5th ed. Philadelphia: J. B. Lipincott; 1986. p. 1331.

    Google Scholar 

  7. Amdur RJ, Mazzaferri EL (2005) The value of a post treatment whole body scan. In Amdur RJ, Mazzaferri EL, editors. Essentials of thyroid cancer management. New York: Springer, pp 65–8

  8. Souza Rosário PW, Barroso AL, Rezende LL, Padrão EL, Fagundes TA, Penna GC, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med. 2004;29:795–8.

    Article  PubMed  Google Scholar 

  9. Becker D, Charkes ND, Dworkin H, Hurley J, McDougall IR, Price D, et al. Procedure guideline for extended scintigraphy for differentiated thyroid cancer: 1.0. J Nucl Med. 1996;37:1269–71.

    CAS  PubMed  Google Scholar 

  10. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.

    Article  CAS  PubMed  Google Scholar 

  11. Nĕmec J, Röhling S, Zamrazil V, Pohunková D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med. 1979;20:92–7.

    PubMed  Google Scholar 

  12. Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med. 2000;41:1198–202.

    CAS  PubMed  Google Scholar 

  13. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28:639–45.

    Article  CAS  PubMed  Google Scholar 

  14. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.

    Article  CAS  PubMed  Google Scholar 

  15. Mazzaferri EL. Empirically treating high serum thyroglobulin levels. J Nucl Med. 2005;46:1079–88.

    PubMed  Google Scholar 

  16. Hindié E, Mellière D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging. 2003;30:974–81.

    Article  PubMed  Google Scholar 

  17. Hung BT, Huang SH, Huang YE, Wang PW. Appropriate time for post-therapeutic I-131 whole body scan. Clin Nucl Med. 2009;34:339–42.

    Article  PubMed  Google Scholar 

  18. Altman D. Practical statistics for medical research, 1st ed. London: Chapman & Hall/CRC; 1991. p. 403–7.

    Google Scholar 

  19. Khan S, Waxman A, Nagaraj N, Braunstein G (1994) Optimization of post ablative I-131 scintigraphy: comparison of 2 day vs. 7 day post therapy study in patients with differentiated thyroid cancer (DTC). J Nucl Med 35:15

    Google Scholar 

  20. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid. 2002;12:707–11.

    Article  CAS  PubMed  Google Scholar 

  21. Coakley AJ, Page CJ, Croft D. Scanning dose and detection of thyroid metastases. J Nucl Med. 1980;21:803–4.

    CAS  PubMed  Google Scholar 

  22. Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodine symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging. 2010;44:4–14.

    Article  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Chonnam National University Medical School, #8 Hak-dong, Dong-gu, Gwangju, 501-757, Korea

    Ari Chong, Ho-Chun Song, Jung-Joon Min, Jahae Kim, Su-Ung Yoo, Jong-Ryool Oh & Hee-Seung Bom

  2. Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, Korea

    Shin Young Jeong

  3. Department of Nuclear Medicine, Chosun University Hospital, Gwangju, Korea

    Jung-Min Ha

Authors
  1. Ari Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ho-Chun Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jung-Joon Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shin Young Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jung-Min Ha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jahae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Su-Ung Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jong-Ryool Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hee-Seung Bom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ho-Chun Song.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chong, A., Song, HC., Min, JJ. et al. Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer. Nucl Med Mol Imaging 44, 273–281 (2010). https://doi.org/10.1007/s13139-010-0051-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-010-0051-y

Keywords

Search

Navigation